<div id="readability-page-1"><div> NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp. (&#34;GeneDx&#34; or the &#34;Company&#34;) (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. <img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="400" height="75" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg"/> The investigation concerns whether GeneDx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On May 4, 2026, GeneDx reported its first quarter 2026 financial results and updated its full-year outlook. Among other things, the Company disclosed total revenue of $102.3 million, exome and genome revenue of $90.6 million, and exome and genome test volume growth of 34% year-over-year. Despite this strong volume growth, GeneDx disclosed that exome and genome revenue increased only 27% year-over-year. The Company also reduced its full-year 2026 revenue guidance to $475 million to $490 million, compared to prior guidance of $540 million to $555 million, and reduced its expected growth in exome and genome revenue to at least 20%, compared to prior guidance of 33% to 35%. During the associated earnings call, GeneDx further disclosed that total revenue was approximately $12 million below expectations, including approximately $5.5 million due to a lower-than-expected blended average reimbursement rate for exome and genome testing, and approximately $6.5 million due to softer-than-expected performance from non-core business lines. On this news, GeneDx's stock price fell $33.42 per share, or 49.20%, to close at $34.51 per share on May 5, 2026.Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP dpeyton@pomlaw.com 646-581-9980 ext. 7980 <img src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wNS0wNyZzbj1EQzU0NjI5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="16" height="16" original-src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wNS0wNyZzbj1EQzU0NjI5"/> View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-genedx-holdings-corp---wgs-302766315.htmlSOURCE Pomerantz LLP</div></div>

標普生物技術 3 倍做多 - Direxion

基因改革 ETF - ARK

Pomerantz 律師事務所正在代表 GeneDx Holdings Corp.（納斯達克：WGS）的投資者調查有關潛在證券欺詐或非法商業行為的索賠。GeneDx 最近公佈了 2026 年第一季度財務業績，顯示總收入為 1.023 億美元，但將全年收入指引下調至 4.75 億至 4.90 億美元，低於之前的 5.40 億至 5.55 億美元。此消息發佈後，GeneDx 的股價暴跌 49.20%，降至每股 34.51 美元。鼓勵投資者聯繫 Pomerantz 以獲取有關加入集體訴訟的更多信息

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS

MorningStar

GeneDx

醫療業 ETF - SPDR

標普生物技術 ETF - SPDR

生物科技 ETF - VanEck Vectors

基因免疫&健康關懷 ETF - iShares

醫藥突破 ETF - ALPS

納斯達克生物科技指數 ETF - iShares Nasdaq

2 倍做多納斯達克生物技術 ETF - ProShares

紐交所高增長板生物技術指數 ETF - First Trust

動態生物技術與基因組 ETF - Invesco

GeneDx - CW27

投資者警報：Pomerantz 律師事務所代表 GeneDx Holdings Corp.的投資者進行索賠調查 - WGS